OHSU
Return to Listing

2 result(s) for Tasinga

PI Name Protocol # Title
Brian Druker IRB00009554 A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment.
Michael Heinrich IRB00009741 A phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase (CML-CP) Patients who achieve and sustain MR4.5 after switching to nilotinib
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program